L’objectif de notre étude est d’évaluer la concordance sur le stade FIGO entre l’IRM pré-thérapeutique et l’analyse anatomopathologique de la pièce opératoire et d’évaluer la concordance sur le grade histologique entre la biopsie d’endomètre et l’analyse de la pièce opératoire

Etude des facteurs cliniques associés à la survie des malades

Etude des facteurs cliniques associés à la réponse à l'immunothérapie

Etude des facteurs cliniques associés la PFS sous immunothérapie

Le but de cette étude est d’évaluer l’intérêt, les enjeux et les modalités de la technique de radiothérapie de rattrapage en escalade de dose dans les cancers de prostate en rechute macroscopique dans la loge de prostatectomie.

Objectif principal :

Identifier des facteurs cliniques, biologiques et tumoraux liés à la résistance à la chimiothérapie aux sels de platine chez des personnes traitées pour un cancer de l’ovaire.

Objectifs secondaires :

• Identifier et valider de nouveaux biomarqueurs pronostiques de l’évolution de la pathologie et prédictifs de réponses aux traitements.
• Evaluer l’impact des stratégies thérapeutiques sur la survenue de la récidive, sur la survie globale et sur la survie sans récidive.

Impact of the histological margin quality at initial surgery (R0 from the outset vs. R0 after revision surgery) on local relapse-free survival;

a. Impact of the histological margin quality at initial treatment (R0 from the outset vs. R0 after revision surgery) on overall survival.

b. Impact of the histological margin quality at initial surgery (R0 vs R1 vs R2 from the first surgical sequence (before any revision)) on overall survival.

c. Impact of the histological margin quality at initial surgery (R0 vs R1 vs R2 from the first surgical sequence (before any revision)) on local relapse-free survival.

d. Impact of the histological margin quality at initial surgery (R0 initial surgery with or without re-excision) on overall survival.

e. Impact of the histological margin quality at initial surgery (R0 initial surgery with or without re-excision) on local relapse-free survival.

f. Determination of initial treatment parameters which are prognostic for local relapse-free survival : histological subtype, size of tumor, grade, site of tumor, radiation area, biopsy before surgery, pre-operative imaging, neoadjuvant treatment before surgery, quality of first surgery, re-excision, surgeon inside or outside network, early metastasis.

g. Determination of initial treatment parameters which are prognostic for overall survival : histological subtype, size of tumor, grade, site of tumor, radiation area, biopsy before surgery, pre-operative imaging, neoadjuvant treatment before surgery, quality of first surgery, re-excision, surgeon inside or outside network, early metastasis. a. Impact of the histological margin quality at initial treatment (R0 from the outset vs. R0 after revision surgery) on overall survival.

b. Impact of the histological margin quality at initial surgery (R0 vs R1 vs R2 from the first surgical sequence (before any revision)) on overall survival.

c. Impact of the histological margin quality at initial surgery (R0 vs R1 vs R2 from the first surgical sequence (before any revision)) on local relapse-free survival.

d. Impact of the histological margin quality at initial surgery (R0 initial surgery with or without re-excision) on overall survival.

e. Impact of the histological margin quality at initial surgery (R0 initial surgery with or without re-excision) on local relapse-free survival.

f. Determination of initial treatment parameters which are prognostic for local relapse-free survival : histological subtype, size of tumor, grade, site of tumor, radiation area, biopsy before surgery, pre-operative imaging, neoadjuvant treatment before surgery, quality of first surgery, re-excision, surgeon inside or outside network, early metastasis.

g. Determination of initial treatment parameters which are prognostic for overall survival : histological subtype, size of tumor, grade, site of tumor, radiation area, biopsy before surgery, pre-operative imaging, neoadjuvant treatment before surgery, quality of first surgery, re-excision, surgeon inside or outside network, early metastasis. a. Impact of the histological margin quality at initial treatment (R0 from the outset vs. R0 after revision surgery) on overall survival.

b. Impact of the histological margin quality at initial surgery (R0 vs R1 vs R2 from the first surgical sequence (before any revision)) on overall survival.

c. Impact of the histological margin quality at initial surgery (R0 vs R1 vs R2 from the first surgical sequence (before any revision)) on local relapse-free survival.

d. Impact of the histological margin quality at initial surgery (R0 initial surgery with or without re-excision) on overall survival.

e. Impact of the histological margin quality at initial surgery (R0 initial surgery with or without re-excision) on local relapse-free survival.

f. Determination of initial treatment parameters which are prognostic for local relapse-free survival : histological subtype, size of tumor, grade, site of tumor, radiation area, biopsy before surgery, pre-operative imaging, neoadjuvant treatment before surgery, quality of first surgery, re-excision, surgeon inside or outside network, early metastasis.

g. Determination of initial treatment parameters which are prognostic for overall survival : histological subtype, size of tumor, grade, site of tumor, radiation area, biopsy before surgery, pre-operative imaging, neoadjuvant treatment before surgery, quality of first surgery, re-excision, surgeon inside or outside network, early metastasis. a. Impact of the histological margin quality at initial treatment (R0 from the outset vs. R0 after revision surgery) on overall survival.

b. Impact of the histological margin quality at initial surgery (R0 vs R1 vs R2 from the first surgical sequence (before any revision)) on overall survival.

c. Impact of the histological margin quality at initial surgery (R0 vs R1 vs R2 from the first surgical sequence (before any revision)) on local relapse-free survival.

d. Impact of the histological margin quality at initial surgery (R0 initial surgery with or without re-excision) on overall survival.

e. Impact of the histological margin quality at initial surgery (R0 initial surgery with or without re-excision) on local relapse-free survival.

f. Determination of initial treatment parameters which are prognostic for local relapse-free survival : histological subtype, size of tumor, grade, site of tumor, radiation area, biopsy before surgery, pre-operative imaging, neoadjuvant treatment before surgery, quality of first surgery, re-excision, surgeon inside or outside network, early metastasis.

g. Determination of initial treatment parameters which are prognostic for overall survival : histological subtype, size of tumor, grade, site of tumor, radiation area, biopsy before surgery, pre-operative imaging, neoadjuvant treatment before surgery, quality of first surgery, re-excision, surgeon inside or outside network, early metastasis.

Etude rétrospective de l’efficacité des sels de platine chez les patients atteints de cancer de la prostate métastatique résistant à la castration avec une mutation d’un des gènes de réparation de l’ADN.

Comparer le taux de séromes post-opératoires chez les patientes bénéficiant d’une mastectomie pour leur cancer du sein, en fonction du capitonnage ou non de la loge.

a) Comparer la survenue des complications post opératoires en fonction du capitonnage ou non de la loge b) Comparer la durée du séjour pour mastectomie en fonction du capitonnage ou non de la loge c) Comparer le nombre de consultations pour ponctions de sérome en fonction du capitonnage de la loge ou non d) Comparer les signes fonctionnels douleur et mobilité articulaire post-opératoire en fonction du capitonnage de la loge ou non

L’objectif principal est d’évaluer la survie globale avant et après l’introduction de l’immunothérapie chez les patients avec un CBNPC avancés.- SGCBNPCAI1

L'objectif du projet est de vérifier la capacité du test Guardant Health 360 à détecter les tumeursréfractaires au traitement un mois après le début d'un traitement par hormonothérapie +inhibiteur de CDH4/6